The Economic Advantage of Single-Source Drug Development and Manufacturing
Supply Chain Management
Tuesday, November 21, 2017

Tufts Center for the Study of Drug Development (CSDD) recently completed research, titled “Assessing the Economics of Single-Source vs. Multi-Vendor Manufacturing” that compared cycle times and development economics between multi- and single-source CDMO models. While there are many studies that debate the total cost of drug development,1-3 the Tufts study sought a better understanding of which model offered the most accelerated time-to-market for its clients. By focusing on time as a primary value driver, a sponsor can lower the overall cost of bringing its drug to market, and more importantly, achieve the speed-to-market patients both want and need.

Be sure to see our short video explaining the benefits of this study here - How can pharma companies save up to $45M in early drug development?


Please complete the short form below to download this whitepaper.  

Looking for Solutions?

We can help.